Can we harness the microbiota to enhance the efficacy of cancer immunotherapy?
- PMID: 32661409
- DOI: 10.1038/s41577-020-0374-6
Can we harness the microbiota to enhance the efficacy of cancer immunotherapy?
Abstract
There is currently much interest in defining how the microbiota shapes immune responses in the context of cancer. Various studies in both mice and humans have associated particular commensal species with better (or worse) outcomes in different cancer types and following treatment with cancer immunotherapies. However, the mechanisms involved remain ill-defined and even controversial. In this Viewpoint, Nature Reviews Immunology has invited six eminent scientists in the field to share their thoughts on the key questions and challenges for the field.
References
-
- Routy, B. et al. Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors. Science 359, 91–97 (2018).
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
